Site icon OncologyTube

2020 TTF ALK SESSION QA PANEL Reducing Dosage on Lorlatinib vs Switching to a Different Agent

Videos from the 2020 Targeted Therapies Patient Forum are still available!

This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

In this video from the ALK session from the event, the panel discusses the reducing dosage on Lorlatiib vs switching to a different agent.

We thank our sponsors for their support of this event! #AstraZeneca #Lilly #Novartis #Takeda #FoundationMedicine #BoehringerIngelheim #BlueprintMedicines #Genentech

Access to the full 2020 agenda can be found here: https://bit.ly/39131em
Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

To join the conversation, visit https://cancergrace.org/forum

Exit mobile version